The denial of the stay removes near-term uncertainty around AbbVie's 340B program revenue. Monitor the Eighth Circuit appeal for a final ruling, but the district court's strong reasoning and the state's delay in seeking the stay suggest a low probability of reversal. This is a modest positive for ABBV's 340B-related earnings stream.
Price Chart
Executive Summary
The District of North Dakota denied North Dakota's motion to stay a permanent injunction pending appeal, keeping AbbVie's win intact. The injunction blocks enforcement of a state law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program, with AbbVie estimating the law cost it $10M in 2025 and would cost another $35M in 2026 in discounted sales. The denial removes near-term uncertainty and preserves AbbVie's ability to operate under the federal program without state-imposed penalties, a material positive for its 340B revenue stream.
Court Ruling Details
Key Facts
- Court denied North Dakota's motion to stay a permanent injunction pending appeal.
- The permanent injunction blocks enforcement of a North Dakota law that AbbVie argued unlawfully interfered with the federal 340B drug pricing program.
- AbbVie estimated the law cost it $10 million in 2025 and will cost another $35 million in 2026 in discounted sales it would not make but for the law.
- The court found North Dakota unlikely to succeed on the merits, citing the law's criminal penalties and direct price regulation as key differences from other state laws.
- The ruling preserves the status quo and prevents North Dakota from re-imposing the law while the appeal proceeds.
Financial Impact
AbbVie estimated the law cost $10M in 2025 and will cost another $35M in 2026 in discounted sales it would not make but for the law. The denial of the stay preserves the injunction, avoiding these costs.
Risk Factors
- The Eighth Circuit could still reverse the permanent injunction on appeal, potentially re-exposing AbbVie to the law's costs.
- Other states may enact similar laws, creating ongoing legal and regulatory risk for the 340B program.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2e6ca3056b-ABBV |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Court Ruling | $261.77 $264.48 | ▲ +1.04% | ▼ −0.62% | $259.94 (−0.70%) |
Sep 3, 2026 29d ago | 8-K | $260.21 $257.12 | ▼ −1.19% | ▼ −0.04% | $259.94 (−0.10%) |
Aug 5, 2026 8w ago | 8-K | $243.87 $250.82 | ▲ +2.85% | ▲ +1.64% | $259.94 (+6.59%) |
Aug 3, 2026 8w ago | Institutional Cluster | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.94 (+6.05%) |
Aug 3, 2026 8w ago | Court Ruling | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.94 (+6.05%) |
Jul 31, 2026 9w ago | 8-K | $250.94 $246.04 | ▼ −1.95% | ▼ −5.46% | $259.94 (+3.59%) |
Jul 27, 2026 9w ago | Court Ruling | $256.91 $250.94 | ▼ −2.32% | ▼ −3.40% | $259.94 (+1.18%) |
Jun 22, 2026 14w ago | 8-K | $230.01 $254.31 | ▲ +10.56% | ▲ +11.02% | $259.94 (+13.01%) |
May 18, 2026 19w ago | Court Ruling | $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $259.94 (+24.13%) |
Apr 29, 2026 22w ago | 8-K | $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $259.94 (+27.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access